TREATMENTS FOR SYSTEMIC LUPUS ERYTHEMATOSUS

摘要

The disclosure involves the identification of the Eukaryotic initiation factor 4 (elF4) machinery as a downstream effector of the B-cell scaffold protein with ankyrin repeats 1 (Bankl )-mediated regulation of IL-6 expression. Thus, methods for treating patients suffering from autoimmune diseases such as systemic lupus erythematosus by targeting elF4 function are provided.